Literature DB >> 21906690

Functional properties and substrate characterization of human CYP26A1, CYP26B1, and CYP26C1 expressed by recombinant baculovirus in insect cells.

Christian Helvig1, Mohammed Taimi, Don Cameron, Glenville Jones, Martin Petkovich.   

Abstract

INTRODUCTION: The cytochrome P450 CYP26 family of retinoic acid (RA) metabolizing enzymes, comprising CYP26A1, CYP26B1, and CYP26C1 is critical for establishing patterns of RA distribution during embryonic development and retinoid homeostasis in the adult. All three members of this family can metabolize all trans-RA. CYP26C1 has also been shown to efficiently metabolize the 9-cis isomer of RA.
METHODS: We have co-expressed each of the CYP26 enzymes along with the NADPH-cytochrome P450 oxidoreductase using a baculovirus/Sf9 insect cell expression system to determine the enzymatic activities of these enzymes in cell free preparations and have established an in vitro binding assay to permit comparison of binding affinities of the three CYP26 enzymes.
RESULTS: We demonstrated that the expressed enzymes can efficiently coordinate heme, as verified by spectral-difference analysis. All CYP26s efficiently metabolized all-trans-RA to polar aqueous-soluble metabolites, and in competition experiments exhibited IC(50) values of 16, 27, and 15nM for CYP26A1, B1, and C1 respectively for all-trans-RA. Furthermore, this metabolism was blocked with the CYP inhibitor ketoconazole. CYP26C1 metabolism of all trans-RA could also be effectively competed with 9-cis RA, with IC(50) of 62nM, and was sensitive to ketoconazole inhibition. DISCUSSION: CYP26 enzymes are functionally expressed in microsomal fractions of insect cells and stably bind radiolabeled RA isomers with affinities respecting their substrate specificities. We demonstrated that compared to CYP26A and CYP26B, only CYP26C1 was able to bind with high affinity to 9-cis-RA. These assays will be useful for the screening of synthetic substrates and inhibitors of CYP26 enzymes and may be applicable to other cytochrome P450s and their respective substrates.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21906690     DOI: 10.1016/j.vascn.2011.08.005

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  13 in total

Review 1.  Human cytochrome P450 enzymes 5-51 as targets of drugs and natural and environmental compounds: mechanisms, induction, and inhibition - toxic effects and benefits.

Authors:  Slobodan P Rendic; F Peter Guengerich
Journal:  Drug Metab Rev       Date:  2018-08       Impact factor: 4.518

2.  Focal facial dermal dysplasia, type IV, is caused by mutations in CYP26C1.

Authors:  Anne M Slavotinek; Pavni Mehrotra; Irina Nazarenko; Paul Ling-Fung Tang; Richard Lao; Don Cameron; Ben Li; Catherine Chu; Chris Chou; Ann L Marqueling; Mani Yahyavi; Kelly Cordoro; Ilona Frieden; Tom Glaser; Trine Prescott; Marie-Anne Morren; Koen Devriendt; Pui-yan Kwok; Martin Petkovich; Robert J Desnick
Journal:  Hum Mol Genet       Date:  2012-11-16       Impact factor: 6.150

Review 3.  Biochemical and physiological importance of the CYP26 retinoic acid hydroxylases.

Authors:  Nina Isoherranen; Guo Zhong
Journal:  Pharmacol Ther       Date:  2019-08-13       Impact factor: 12.310

4.  A CYP26B1 polymorphism enhances retinoic acid catabolism and may aggravate atherosclerosis.

Authors:  Olesya Krivospitskaya; Ali Ateia Elmabsout; Eva Sundman; Leif A Söderström; Olga Ovchinnikova; Andreas C Gidlöf; Nikolai Scherbak; Giuseppe Danilo Norata; Ann Samnegård; Hans Törmä; Samy M Abdel-Halim; Jan-Håkan Jansson; Per Eriksson; Allan Sirsjö; Peder S Olofsson
Journal:  Mol Med       Date:  2012-05-09       Impact factor: 6.354

5.  Importance of ALDH1A enzymes in determining human testicular retinoic acid concentrations.

Authors:  Samuel L Arnold; Travis Kent; Cathryn A Hogarth; Stefan Schlatt; Bhagwat Prasad; Michael Haenisch; Thomas Walsh; Charles H Muller; Michael D Griswold; John K Amory; Nina Isoherranen
Journal:  J Lipid Res       Date:  2014-12-11       Impact factor: 5.922

Review 6.  Therapeutic potential of the inhibition of the retinoic acid hydroxylases CYP26A1 and CYP26B1 by xenobiotics.

Authors:  Cara H Nelson; Brian R Buttrick; Nina Isoherranen
Journal:  Curr Top Med Chem       Date:  2013       Impact factor: 3.295

7.  Identification of Tazarotenic Acid as the First Xenobiotic Substrate of Human Retinoic Acid Hydroxylase CYP26A1 and CYP26B1.

Authors:  Robert S Foti; Nina Isoherranen; Alex Zelter; Leslie J Dickmann; Brian R Buttrick; Philippe Diaz; Dominique Douguet
Journal:  J Pharmacol Exp Ther       Date:  2016-03-02       Impact factor: 4.030

8.  Comparison of the ligand binding site of CYP2C8 with CYP26A1 and CYP26B1: a structural basis for the identification of new inhibitors of the retinoic acid hydroxylases.

Authors:  Robert S Foti; Philippe Diaz; Dominique Douguet
Journal:  J Enzyme Inhib Med Chem       Date:  2016-07-17       Impact factor: 5.051

9.  CYP26C1 Is a Hydroxylase of Multiple Active Retinoids and Interacts with Cellular Retinoic Acid Binding Proteins.

Authors:  Guo Zhong; David Ortiz; Alex Zelter; Abhinav Nath; Nina Isoherranen
Journal:  Mol Pharmacol       Date:  2018-02-23       Impact factor: 4.436

10.  Drivers and suppressors of triple-negative breast cancer.

Authors:  Wanfu Wu; Margaret Warner; Li Wang; Wei-Wei He; Ruipeng Zhao; Xiaoxiang Guan; Cindy Botero; Bo Huang; Charlotte Ion; Charles Coombes; Jan-Ake Gustafsson
Journal:  Proc Natl Acad Sci U S A       Date:  2021-08-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.